Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria

West African Journal of Medicine

Volumn 24, Issue 3, 2005, Pages 209-212

  Gukas, I D ^a   Jennings, B A ^a   Mandong, B M ^b   Igun, G O ^b   Girling, A C ^c   Manasseh, A N ^b   Ugwu, B T ^b   Leinster, S J ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF JOS   (Nigeria)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Grade; Jos; Molecular markers; Stage

Indexed keywords

AVIDIN; BIOTIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MOLECULAR MARKER; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER STAGING; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; NIGERIA; PAGET NIPPLE DISEASE; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; NIGERIA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 28344432625     PISSN: 0189160X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2: 133-40.
2. Ihekwaba FN. Breast cancer in Nigerian wome Br J Surg 1992; 79: 771-5.
3. Adebamowo CA, Ajayi OO. Breast cancer in Nigeria. West Afr J Med 2000; 19: 179-91.
4. Ihezue CH, Ugwu BT, Nwana EJ. Breast cancer in Highlanders. Nigerian Journal of Surgical Sciences 1994; 4: 1-4.
5. Hassan I, Onukak EE, Mabogunje OA. Breast cancer in Zaria, Nigeria. J R Coll Surg Edinb 1992; 37: 159-61.
6. Okobia MN, Osime U. Clinicopathological study of carcinoma of the breast in Benin City. Afr J Reprod Health 2001; 5: 56-62.
7. Gwyn K, Bondy ML, Cohen DS et al. Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer 2004; 100: 1595-604.
8. Elledge RM, Clark GM, Chamness GC, et al. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994; 86: 705-12.
9. Leinster SJ. Impact of molecular biology on the clinical management of breast cancer. Biochem Soc Symp 1998; 63: 185-91.
10. Sledge GW Jr., Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer 2003; 39: 1668-75.
11. Dimitrakakis C, Konstadoulakis M, Messaris E et al. Molecular markers in breast cancer: can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors? Breast 2002; 11: 279-85.
12. Leonard DS, Hill AD, Kelly L, et al. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br J Surg 2002; 89: 262-71.
13. Ikpat OF, Ndoma-Egba R, Collan Y. Influence of age and prognosis of breast cancer in Nigeria. East Afr Med J 2002; 79: 651-7.
14. Adebamowo CA, Adekunle OO. Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br J Surg 1999; 86: 665-8.
15. Ijaduola TG, Smith EB. Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. J Natl Med Assoc 1998; 90: 547-51.
16. Rose DP, Royak-Schaler R. Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev 2001; 25: 16-31.
17. National Population Commission of Nigeria. 1991 Population Census of the Federal Republic of Nigeria: Analytical Report at the National Level. Abuja, Nigeria: National Population Commission of Nigeria, 1998.
18. Ikpatt OF, Kuopio T, Ndoma-Egba R,et al. Breast cancer in Nigeria and Finland: epidemiological, clinical and histological comparison. Anticancer Res 2002; 22: 3005-12.
19. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 2003; 163: 49-56.
20. Moss SM, Michel M, Patnick J, et al. Results from the NHS breast screening programme 1990-1993. J Med Screen 1995; 2: 186-90.
21. Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275: 913-8.
22. Walker RA, Lees E, Webb MB, et al. Breast carcinomas occurring in young women (< 35 years) are different. Br J Cancer 1996; 74: 1796-800.
23. Northridge ME, Rhoads GG, Wartenberg D, et al. The importance of histologic type on breast cancer survival. J Clin Epidemiol 1997; 50: 283-90.
24. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 2002; 11: 601-7.
25. Chen VW, Correa P, Kurman RJ et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 1994; 3: 127-35.
26. Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat 2002; 73: 45-59.
27. Poola I, Clarke R, DeWitty R, et al. Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are different from the profiles in breast tumors of Caucasian women. Cancer 2002; 94: 615-23.
28. NIH Concensus Development Conference on Steroid Receptor in Breast Cancer. Cancer 1980; 46: 2759-963.
29. Senbanjo RO, Ihekwaba FN, Ajayi OO. Tamoxifen in the management of advanced breast carcinoma in Nigerian women. West Afr J Med 1990; 9: 44-9.
30. Key TJ, Verkasalo PK. Endogenous hormones and the aetiology of breast cancer. Breast Cancer Res 1999; 1: 18-21.
31. Taioli E, Bradlow HL, Garbers SV et al. Role of oestradiol metabolism and CYP1A1 polymorphism in breast cancer risk. Cancer Detection and Prevention 1999; 23: 232-7.
32. Kristensen VN, Borresen-Dale AL. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res 2000; 462: 323-33.
33. Nagai MA, Schaer Barbosa H, Zago MA et al. TP53 mutations in primary breast carcinomas from white and African-Brazilian patients. Int J Oncol 2003; 23: 189-96.
34. Shiao YH, Chen VW, Wu XC et al. Racial comparison of p53 alterations in breast cancer: difference in prognostic value. In Vivo 1996; 10: 169-73.
35. Geisler S, Borresen-Dale AL, Johnsen H et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003; 9: 5582-8.
36. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998; 52: 1-15.
37. Lamb J, Ladha MH, McMahon C, et al. Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol 2000; 20: 8667-75.
38. Joe AK, Arber N, Bose S et al. Cyclin D1 overexpression is more prevalent in non-Caucasian breast cancer. Anticancer Res 2001; 21: 3535-9.
39. Krieger N, van den Eeden SK, Zava D, et al. Race/ethnicity, social class, and prevalence of breast cancer prognostic biomarkers: a study of white, black, and Asian women in the San Francisco bay area. Ethn Dis 1997; 7: 137-49.